<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary pulmonary <z:hpo ids='HP_0100243'>leiomyosarcoma</z:hpo> (LMS) is a very unusual <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although LMS has well-known metastatic potential, <z:e sem="disease" ids="C0153687" disease_type="Neoplastic Process" abbrv="">cutaneous metastasis</z:e> is a remarkably uncommon </plain></SENT>
<SENT sid="2" pm="."><plain>Exposure to cytotoxic agents could lead to "therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasm</z:hpo>" (t-MN) </plain></SENT>
<SENT sid="3" pm="."><plain>Starting from 2008, the World Health Organization (WHO) has adopted the term to cover the spectrum of malignant diseases previously known as therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and therapy-related myelodysplastic/myelo- proliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN) </plain></SENT>
<SENT sid="4" pm="."><plain>We described the <z:hpo ids='HP_0003674'>onset</z:hpo> of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and progression to t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in one case diagnosed as primary pulmonary LMS with <z:e sem="disease" ids="C0153687" disease_type="Neoplastic Process" abbrv="">cutaneous metastasis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>This patient achieved complete remission (CR) after three courses of IA regimen chemotherapy (<z:chebi fb="0" ids="42068">idarubicin</z:chebi> 5 mg/d, d 1-3; <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 100 mg/d, d 1-5) and 1 course of HA chemotherapy regimen (homoharringtonine 3 mg/d, d 1-3; <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 100 mg/d, d 1-7) </plain></SENT>
<SENT sid="6" pm="."><plain>This case presents the natural course of therapy-related <z:hpo ids='HP_0002664'>neoplasm</z:hpo> and provides therapeutic experience for t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>